C. Ian Mortimer's most recent trade in Xenon Pharmaceuticals Inc was a trade of 12,500 Restricted Share Units done . Disclosure was reported to the exchange on March 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 12,500 | 37,500 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2026 | 12,500 | 27,231 (0%) | 0% | - | Common Shares | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 55.22 per share. | 12 Mar 2026 | 7,308 | 19,923 (0%) | 0% | 55.2 | 403,584 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 105,000 | 0 | - | - | Stock Option | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. | 09 Mar 2026 | 105,000 | 111,000 (0%) | 0% | 4.8 | 498,750 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 75,000 | 0 | - | - | Stock Option | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.40 per share. | 09 Mar 2026 | 75,000 | 81,000 (0%) | 0% | 8.4 | 630,000 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. | 09 Mar 2026 | 65,000 | 71,000 (0%) | 0% | 9.4 | 613,600 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 65,000 | 0 | - | - | Stock Option | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 62.06 per share. | 09 Mar 2026 | 65,000 | 6,000 (0%) | 0% | 62.1 | 4,033,900 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 60.08 per share. | 09 Mar 2026 | 61,652 | 6,000 (0%) | 0% | 60.1 | 3,704,052 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 59.26 per share. | 09 Mar 2026 | 43,348 | 72,652 (0%) | 0% | 59.3 | 2,568,802 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 59.88 per share. | 09 Mar 2026 | 31,694 | 27,515 (0%) | 0% | 59.9 | 1,897,837 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 25,000 | 0 | - | - | Stock Option | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.10 per share. | 09 Mar 2026 | 25,000 | 31,000 (0%) | 0% | 3.1 | 77,500 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 58.81 per share. | 09 Mar 2026 | 21,791 | 59,209 (0%) | 0% | 58.8 | 1,281,529 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 60.49 per share. | 09 Mar 2026 | 21,515 | 6,000 (0%) | 0% | 60.5 | 1,301,442 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 20,000 | 0 | - | - | Performance Share Units | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2026 | 20,000 | 20,000 | - | - | Performance Share Units | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 20,000 | 26,000 (0%) | 0% | - | Common Shares | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 59.50 per share. | 09 Mar 2026 | 12,479 | 18,521 (0%) | 0% | 59.5 | 742,501 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 60.11 per share. | 09 Mar 2026 | 11,269 | 14,731 (0%) | 0% | 60.1 | 677,357 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 60.47 per share. | 09 Mar 2026 | 10,072 | 8,449 (0%) | 0% | 60.5 | 609,054 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 61.26 per share. | 09 Mar 2026 | 2,449 | 6,000 (0%) | 0% | 61.3 | 150,026 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 350,000 | 350,000 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2026 | 65,000 | 65,000 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | C. Ian Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.49 per share. | 02 Jan 2026 | 40,000 | 46,000 (0%) | 0% | 7.5 | 299,600 | Common Shares |
| Xenon Pharma Inc | Mortimer C. Ian | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Mortimer Ian C. | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 44.40 per share. | 02 Jan 2026 | 37,938 | 8,062 (0%) | 0% | 44.4 | 1,684,447 | Common Shares |
| Xenon Pharma Inc | Mortimer C. Ian | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 44.93 per share. | 02 Jan 2026 | 2,062 | 6,000 (0%) | 0% | 44.9 | 92,646 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 45.03 per share. | 05 Dec 2025 | 14,375 | 16,830 (0%) | 0% | 45.0 | 647,306 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 45.59 per share. | 05 Dec 2025 | 8,820 | 8,010 (0%) | 0% | 45.6 | 402,104 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 46.32 per share. | 05 Dec 2025 | 2,010 | 6,000 (0%) | 0% | 46.3 | 93,103 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 28 Nov 2025 | 97 | 31,205 (0%) | 0% | 45.0 | 4,366 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT, CEO & INTERIM CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT, CEO & INTERIM CFO | Sale of securities on an exchange or to another person at price $ 40.16 per share. | 01 Oct 2025 | 25,000 | 31,302 (0%) | 0% | 40.2 | 1,004,000 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT, CEO & INTERIM CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.69 per share. | 01 Oct 2025 | 25,000 | 56,302 (0%) | 0% | 7.7 | 192,250 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 275,000 | 275,000 | - | - | Share Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 50,000 | 50,000 | - | - | Restricted Share Units | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 22,468 | 53,770 (0%) | 0% | 17.8 | 399,032 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.20 per share. | 23 Jan 2025 | 22,468 | 31,302 (0%) | 0% | 40.2 | 903,214 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 22,468 | 16,315 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,315 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 16,217 | 47,519 (0%) | 0% | 17.8 | 288,014 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 23 Jan 2025 | 16,217 | 31,302 (0%) | 0% | 40.1 | 649,977 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,217 | 38,783 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 15,166 | 46,468 (0%) | 0% | 17.8 | 269,348 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.46 per share. | 23 Jan 2025 | 15,166 | 31,302 (0%) | 0% | 40.5 | 613,616 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 1,149 | 32,451 (0%) | 0% | 17.8 | 20,406 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 23 Jan 2025 | 1,149 | 31,302 (0%) | 0% | 41.1 | 47,189 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 42,592 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. | 24 May 2023 | 42,592 | 48,592 (0%) | 0% | 9.4 | 402,068 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 20,576 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. | 24 May 2023 | 20,576 | 44,789 (0%) | 0% | 9.9 | 202,674 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.44 per share. | 24 May 2023 | 17,069 | 24,213 (0%) | 0% | 41.4 | 707,339 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.37 per share. | 24 May 2023 | 13,179 | 27,708 (0%) | 0% | 41.4 | 545,215 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 7,310 | 41,282 (0%) | 0% | 41.8 | 305,850 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 6,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. | 24 May 2023 | 6,172 | 33,880 (0%) | 0% | 9.8 | 60,794 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 3,902 | 40,887 (0%) | 0% | 41.8 | 163,260 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.49 per share. | 24 May 2023 | 1,407 | 31,302 (0%) | 0% | 41.5 | 58,376 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 1,171 | 32,709 (0%) | 0% | 41.8 | 48,995 | Common Shares |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 380,000 | 380,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharma Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) |